Home
About Us
Membership
Member Biography

Member Biography

Theodore F. Logan, MD

Theodore F. Logan, M.D.

Phone: (317) 948-7576
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
RT 473
Indianapolis, IN 46202
Fax: (317) 948-7444

Faculty appointments

Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Affiliate member

The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Advanced Melanoma09-333

A PHASE II STUDY OF COMBINING TALIMOGENE LAHERPAREPVEC (T-VEC) (NSC-785349) AND MK-3475 (PEMBROLIZUMAB) (NSC-776864) IN PATIENTS WITH ADVANCED MELANOMA WHO HAVE PROGRESSED ON ANTI-PD1/L1 BASED THERAPYS1607

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV MelanomaEA6141

Retrospective Review of Patients Ineligible for High Dose Interleukin-2 Due To Inadequate Organ Function and Treated With Intermediate Dose IL-2 Bolus for Renal Cell CarcinomaIUCRO-0388

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic MelanomaC-144-01

Bridging the Gap: Understanding and addressing utilization of immunotherapy for advanced melanomaBRIDGING-THE-GAP

A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.S1404

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumuab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFFV600 Mutant MelanomaEA6134

Description of Cardiotoxicity Associated with Sunitinib in Renal Cell CarcinomaIUSCC-0645

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2αinhibitor, to investigate safety, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced clear cell renal cell carcinomaNKT2152-101

Blood Drawing for Study of Peripheral Blood T-Lymphocytes and Other Parameters in patients with Metastatic Melanoma and Renal Cell Cancer with Spontaneous RegressionIUCRO-0042

Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell CarcinomaIUCRO-0049

Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b No, T3a-bNo, T4a-b No, and T1-4, N1a, 2a (microscopic) MelanomaE1697

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.E2810

A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV MelanomaE3612

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma.CA209-214

Headlines & highlights

Dr. Logan provides immunotherapy expertise (June 2016)

#ResearchCuresCancer

Support Our Research